RNA therapy

RNA strand
#Arrowhead Pharmaceuticals #Cardiovascular disease #Phase II trial #RNA therapy

Arrowhead’s RNA therapy silences two genes simultaneously

Arrowhead Pharmaceuticals has announced interim topline data from a Phase I/IIa clinical trial of ARO-DIMER-PA, the company’s first investigational RNA interference (RNAi) therapeutic dimer being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia.   ARO-DIMER-PA is designed to silence expression of both… Read More

#News

#Cardiomyopathy #Drug development #Drug discovery #FDA #HAYA Therapeutics #nHCM #RNA therapy #Symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM) #US Food and Drug Administration (FDA)

Treatment underway for nonobstructive hypertrophic cardiomyopathy 

The US Food and Drug Administration (FDA) has granted Fast Track Designation for HAYA Therapeutics’ HTX-001 for the treatment of symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM).   The first-in-class investigational long non-coding RNA (lncRNA)-targeting therapy is in a Phase Ia/b trial, with the first cohort dosed this past May.  HTX-001 is a… Read More

#News